



State-of-the-Art Vaccine Research in AustralAsia

Guest Editor:

Dr. Mariusz Skwarczynski

School of Chemistry and
Molecular Biosciences, The
University of Queensland, St
Lucia, QLD 4072, Australia

Deadline for manuscript
submissions:

closed (31 January 2025)

Message from the Guest Editor

Asia and Australia are globally renowned for their research on vaccine development, which also includes extensive efforts toward the development of SARS-CoV-2 vaccines. Indeed, there is a large number of research teams devoting their work to vaccine development across Australasian countries. Moreover, many countries have their own medical research center/institute working on many aspects of vaccine development; these include the following, to mention a few: Eliza Hall Institute of Medical Research and Doherty Institute (Australia), Center for Vaccine and Adjuvant Research and Institute for Vaccine Research and Development (Japan), International Vaccine Institute (Korea), Beijing Institute of Biotechnology, Chinese PLA Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases (China), and Malaysian Genome and Vaccine Institute (Malaysia).

This Special Issue is devoted to vaccine development in Australia and Asia. The Special Issue is expected to promote vaccine work from Australasia worldwide. Research articles and reviews are welcome, as long as they provide a consolidated view of the state of the art in this area.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)